Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia.
- VernacularTitle:地西他滨联合IAG方案治疗老年MDS转化为急性髓系白血病患者的疗效观察
- Author:
Yue-Qin HUANG
1
;
Xue-Ya ZHANG
2
;
Shi-Xin WU
1
;
Xi-Zhe GUO
1
;
Jing-Xin PAN
1
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(6):1641-1646
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the curative effect and safety of decitabine combined with IAG regimen for treating senile MDS-transformed AML patients.
METHODSTwo cases of senile MDS-transformed AML were treated with decitabine combined with IAG regimen (decitabine 25 mg/d,qd,ivgtt,d1-5,Idarubicin 10 mg/d,qd,ivgtt,d6,Ara-C 10 mg/m,q12h, sc,d 6-19,G-CSF 300 µg,qd,ih,d6-19). The efficacy and adverse reactions were observed in these cases.
RESULTS1 case for 2 courses and 1 case for 1 course obtained complete remission(CR). The myelosuppression and infections due to neutropenia were the most frequent adverse effects, the severe nonhematologic toxicity, such as liver and kidney and gastrointestinal reactions, were not observed in these patients.
CONCLUSIONDecitabine combined with IAG regimen is an effective for treating senile MDS-transformed AML patients.
